share_log

10-K: Annual report

10-K: Annual report

10-K：年度報表
美股sec公告 ·  04/16 17:11
Moomoo AI 已提取核心訊息
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
醫療技術公司SeaStar Medical報告稱，截至2023年12月31日的年度淨虧損爲2620萬美元，而上一年的淨虧損爲1,220萬美元，增長了115％。該公司的累計赤字從同比的8,850萬美元增至約1.147億美元。在臨床試驗費用和工資的推動下，研發費用增長了139％，達到597.3萬美元，而由於保險、美國證券交易委員會報告費和法律費用增加，一般和管理費用增長了19％，達到823.7萬美元。SeaStar Medical尚未從商業化產品中產生可觀的收入，其業務主要通過股權證券、可轉換債務和補助金提供資金。截至2023年12月31日，該公司的現金狀況約爲20萬美元，高於去年的0萬美元。SeaStar Medical的未來計劃包括繼續臨床開發其選擇性細胞移植設備（SCD），以獲得美國食品藥品管理局的批准並最終實現商業化。但是，該公司承認，需要額外的資本來爲運營提供資金，如果有的話，以優惠條件籌集此類資本也存在不確定性。
醫療技術公司SeaStar Medical報告稱，截至2023年12月31日的年度淨虧損爲2620萬美元，而上一年的淨虧損爲1,220萬美元，增長了115％。該公司的累計赤字從同比的8,850萬美元增至約1.147億美元。在臨床試驗費用和工資的推動下，研發費用增長了139％，達到597.3萬美元，而由於保險、美國證券交易委員會報告費和法律費用增加，一般和管理費用增長了19％，達到823.7萬美元。SeaStar Medical尚未從商業化產品中產生可觀的收入，其業務主要通過股權證券、可轉換債務和補助金提供資金。截至2023年12月31日，該公司的現金狀況約爲20萬美元，高於去年的0萬美元。SeaStar Medical的未來計劃包括繼續臨床開發其選擇性細胞移植設備（SCD），以獲得美國食品藥品管理局的批准並最終實現商業化。但是，該公司承認，需要額外的資本來爲運營提供資金，如果有的話，以優惠條件籌集此類資本也存在不確定性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息